Key Points
- Najat Khan, a Recursion insider, sold 124,403 shares on Dec. 22 at an average of $4.41 for a total of $548,617.23, reducing her stake by 16.91% to 611,135 shares (≈$2.70M).
- Recursion reported Q results showing EPS of ($0.36) that beat estimates by $0.02, but revenue plunged 80.1% year-over-year to $5.18M and the company remains deeply unprofitable with very negative net margin and ROE.
- Institutional ownership is high at 89.06%, and analyst coverage is mixed with a consensus rating of "Hold" and an average target price of $9.50 (individual targets range roughly $8–$11).
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) insider Najat Khan sold 124,403 shares of the firm's stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total transaction of $548,617.23. Following the sale, the insider directly owned 611,135 shares of the company's stock, valued at approximately $2,695,105.35. The trade was a 16.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Recursion Pharmaceuticals Stock Performance
Shares of RXRX stock opened at $4.13 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.60 and a quick ratio of 4.60. The company's fifty day moving average price is $4.73 and its two-hundred day moving average price is $5.10. The firm has a market capitalization of $2.15 billion, a P/E ratio of -2.29 and a beta of 0.94. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $19.36 million. During the same period last year, the firm earned ($0.34) earnings per share. The company's revenue was down 80.1% on a year-over-year basis. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of RXRX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Recursion Pharmaceuticals by 183.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock valued at $33,901,000 after buying an additional 4,149,346 shares during the last quarter. Vanguard Group Inc. boosted its stake in Recursion Pharmaceuticals by 10.3% in the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company's stock valued at $194,127,000 after acquiring an additional 3,708,975 shares during the period. Norges Bank bought a new position in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $16,040,000. Bank Pictet & Cie Europe AG acquired a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter worth approximately $7,954,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 20.7% in the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company's stock worth $39,353,000 after purchasing an additional 1,332,428 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
RXRX has been the subject of several research analyst reports. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Needham & Company LLC reissued a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $9.50.
Read Our Latest Report on RXRX
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
